STATISTICAL ANALYSIS PLAN

Study Title
Multicenter, open-label trial evaluating the efficacy and safety of perampanel added to monotherapy in patients with partial onset seizures with or without secondary generalized seizures

Protocol No./ Version
E2007-M065-412 / v2.1

Sponsor
Eisai Korea Inc.

Version No. (Version Date)
V1.0 (15-Jun-2018)

Written By
PPD / Biostatistician

C&R Research
Signature page (C&R)

Prepared by:

Name/ Role  Signature  Date (DD-MMM-YYYY)

Reviewed by:

Name/ Role  Signature  Date (DD-MMM-YYYY)

Approved by:

Name/ Role  Signature  Date (DD-MMM-YYYY)
Signature page (Sponsor)

Reviewed by:

<table>
<thead>
<tr>
<th>Name/ Role</th>
<th>Signature</th>
<th>Date (DD-MMM-YYYY)</th>
</tr>
</thead>
</table>

Approved by:

<table>
<thead>
<tr>
<th>Name/ Role</th>
<th>Signature</th>
<th>Date (DD-MMM-YYYY)</th>
</tr>
</thead>
</table>
**Version Information** (Document revision history)

<table>
<thead>
<tr>
<th>Version</th>
<th>Effective Date</th>
<th>Prepared by Name</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Sponsor’s approval date</td>
<td>PPD</td>
<td>First version</td>
</tr>
</tbody>
</table>
## Abbreviation

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>Adverse Drug Reaction</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse Events</td>
</tr>
<tr>
<td>ATC code</td>
<td>Anatomical Therapeutic Chemical code</td>
</tr>
<tr>
<td>FAS</td>
<td>Full Analysis Set</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>PPS</td>
<td>Per-Protocol Set</td>
</tr>
<tr>
<td>PT</td>
<td>Preferred Term</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>SOC</td>
<td>System Organ Class</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedure</td>
</tr>
<tr>
<td>WHODD</td>
<td>WHO Drug Dictionary</td>
</tr>
</tbody>
</table>
## Contents

**Signature page (Sponsor)** .............................................................................................................. 3  
**Version Information** (Document revision history) ........................................................................... 4  
**Abbreviation** ................................................................................................................................... 5  
1. Study Design ............................................................................................................................. 8  
2. Study Objectives ........................................................................................................................... 9  
3. Justification of Sample Size ....................................................................................................... 9  
4. Efficacy and Safety Endpoints ................................................................................................... 10  
   4.1 Efficacy Endpoints ........................................................................................................ 10  
      4.1.1 Primary Efficacy Endpoint ......................................................................................... 10  
      4.1.2 Secondary Efficacy Endpoints .................................................................................... 10  
   4.2 Safety Endpoints .................................................................................................................. 11  
5. Analysis Sets .............................................................................................................................. 11  
   5.1 Efficacy Analysis Set ........................................................................................................ 11  
   5.2 Safety Analysis Set ............................................................................................................ 11  
6. Statistical Analysis Method ....................................................................................................... 12  
   6.1 Analysis Program .............................................................................................................. 12  
   6.2 General Principles of Result Analysis .............................................................................. 12  
   6.3 Handling of Withdrawal and Missing Data ...................................................................... 12  
   6.4 Adjustment for covariate ................................................................................................. 12  
   6.5 Multiple Comparison or Multiplicity of Testing ............................................................... 12  
   6.6 Interim Analysis ................................................................................................................ 12  
   6.7 Sensitivity Analysis .......................................................................................................... 12  
   6.8 Study Participation ........................................................................................................... 13  
      6.8.1 Subject Disposition .................................................................................................... 13  
      6.8.2 Subject Disposition by Study Site ........................................................................... 13  
      6.8.3 Protocol Deviation ..................................................................................................... 13  
      6.8.4 Analysis Sets ............................................................................................................. 13  
   6.9 Demographic Information ................................................................................................. 13  
   6.10 Treatment Compliance ..................................................................................................... 15  
   6.11 Efficacy Analysis ............................................................................................................. 15  
      6.11.1 Analysis of primary efficacy endpoint ............................................................... 16  
      6.11.2 Analysis of secondary efficacy endpoints ............................................................. 16
6.12 Safety Analysis ................................................................. 18
   6.12.1 Extent or Exposure ......................................................... 18
   6.12.2 Adverse Events ......................................................... 18
   6.12.3 Laboratory Tests ..................................................... 19
   6.12.4 Vital Signs ............................................................... 19
   6.12.5 Physical Measurement (Body Weight) ......................... 19

7. Plan for Revision of Analysis Method .................................... 19

8. TLF shell ........................................................................... 19

9. Roles and Responsibilities ................................................... 22

10. Applied SOPs .................................................................. 22

11. Applied SOP SDs ............................................................ 22
1. Study Design

This is a multicenter, open label, single arm, for therapeutic use, study.

Prior to the study initiation, approval from IRB of each study site as well as written contract is required. Prior to the study participation, patients should receive sufficient explanation about the study and provide written consent regarding the access to and use of personal and medical information. After the consent process, subjects who meet all of the inclusion criteria and none of the exclusion criteria will receive the investigational product (Fycompa film-coated tablet). Information on baseline seizure count (frequency) will be collected retrospectively by the subject or guardian. This study consists of titration period (12 weeks) and maintenance period (24 weeks).

[Titration period (12 weeks)]
Subjects will initiate perampanel at 2 mg/day, which can be increased up to 12 mg by increments of 2 mg no more frequently than at 2-week interval according to the investigator’s judgment. The dose can be maintained or reduced based on the subject’s clinical response and tolerability according to the investigator’s judgment. Subjects who cannot tolerate 4 mg/day will be withdrawn from the study. Subjects who are taking concomitant drugs that shorten the half-life of perampanel (phenytoin, carbamazepine, oxcarbazepine, etc.) will titrate the dose by increments of 2 mg/day no more frequently than at 1-week interval. Adjusting the type or dose of concomitant anti-epileptic drug is not allowed during this period.

[Maintenance period (24 weeks)]
Throughout the maintenance period, subjects will maintain the dose administered at the end of the titration period. However, the dose can be increased to maximum 12 mg/day or reduced to minimum 4 mg/day based on the subject’s clinical response and tolerability according to the
investigator’s judgment. Subjects who reduce the dose during the maintenance period can increase the dose once tolerability is improved. Subjects who cannot tolerate 4 mg/day will be withdrawn from the study. Adjusting the type or dose of concomitant anti-epileptic drug is not allowed during this period.

In case of withdrawal, the dose will be tapered down and follow-up visit will take place 4 weeks after the last dose.

Subjects will visit the site for Visit 1 (Week 0), Visit 2 (Week 6), Visit 3 (Week 12), Visit 4 (Week 24) and Visit 5 (Week 36).

2. Study Objectives

2.1. Primary Objective
To evaluate the efficacy of perampanel added to monotherapy in patients with partial onset seizures with or without secondary generalization as measured by 50% responder rate

2.2. Secondary objectives
1) To evaluate the safety of perampanel added to monotherapy in patients with partial onset seizures with or without secondary generalization
2) To evaluate efficacy of perampanel added to monotherapy in patients with secondary generalized tonic clonic seizure

3. Justification of Sample Size
This study determines the efficacy and safety of perampanel as add-on therapy in patients with partial onset seizure. Primary efficacy endpoint is the 50% responder rate for partial onset seizure with or without secondary generalization. According to Bernhard J. Steinhoff et al., the 50% responder rate was 35.3% in the test group and 19.3% in the control group. To ensure 90% power at two-sided significance level of 5%, 94 subjects are required. Considering 10% drop-out rate, a total of 105 subjects are required.

\[ n = \frac{(Z_{\alpha/2} + Z_\beta)^2 \cdot [p_T(1 - p_T)]}{(p_T - p_R)^2} \]

\[ Z_{\alpha/2} = 1.96, \quad Z_\beta = 1.645 \]

\[ n = \frac{(1.96 + 1.645)^2 \cdot [0.353(1 - 0.353)]}{(0.353 - 0.193)^2} \]
\[
= \frac{(1.96 + 1.282)^2 \ [0.353(1 - 0.353)]}{(0.353 - 0.193)^2}
\]

\[
= 93.77 \approx 94
\]

\(Z_{\alpha/2} : \) Type I error (0.05/2)
\(Z_{\beta} : \) Type II error (0.1)
\(p_T : 50\% \) responder rate in the test group
\(p_R : \) Reference value

4. Efficacy and Safety Endpoints

4.1 Efficacy Endpoints

4.1.1 Primary Efficacy Endpoint
50% responder rate for partial onset seizures with or without secondary generalization: the proportion of subjects achieving at least 50% reduction in the frequency of partial onset seizures with or without secondary generalization during the maintenance period compared to baseline

4.1.2 Secondary Efficacy Endpoints
1) 75% responder rate for partial onset seizures with or without secondary generalization
2) 100% responder (seizure free) rate for partial onset seizures with or without secondary generalization
3) Percent change from baseline in the frequency of partial onset seizures with or without secondary generalization during the titration period and maintenance period
4) 50% responder rate for secondary generalized tonic-clonic seizure
5) 75% responder rate for secondary generalized tonic-clonic seizure
6) 100% responder (seizure free) rate for secondary generalized tonic-clonic seizure
7) Percent change from baseline in the frequency of secondary generalized tonic-clonic seizure during the titration period and maintenance period

* Secondary generalized tonic-clonic seizure is collected as ‘complex partial onset seizure with secondary generalization’
4.2 Safety Endpoints

1) Adverse events
2) Laboratory tests
3) Vital signs
4) Physical measurements

5. Analysis Sets

5.1 Efficacy Analysis Set

Efficacy is analyzed primarily in the Full Analysis Set (FAS), and secondarily in the Per-Protocol Set (PPS). Safety is analyzed in the Safety Analysis Set.

- FAS: subjects who received at least one dose of investigational product and were assessed for primary efficacy at least once during the maintenance period (Week 12 - 5 days ~ Week 36 + 7 days).

- PPS: subjects in FAS who completed the study per protocol without major violation. Subjects who meet any of the following conditions are excluded from PPS.
  1) Deviation from selection criteria
  2) Use of prohibited concomitant medication or therapy
  3) Withdrawal
  4) Deviation from treatment compliance
  5) Other deviation considered as major protocol violation

5.2 Safety Analysis Set

Safety is analyzed in the Safety Analysis Set.

- Safety Analysis Set: subjects who received at least one dose of investigational product and were assessed for safety at least once.
6. Statistical Analysis Method

6.1 Analysis Program
Statistical analysis will use SAS® Version 9.4 (SAS Institute, Cary, NC, USA) or subsequent version.

6.2 General Principles of Result Analysis
All analyses will be descriptive. Continuous variables will be presented using descriptive statistics (number of subjects, mean, standard deviation, median, minimum and maximum), while categorical variables will be presented using frequency and percentage. In addition, with regard to efficacy, 95% confidence interval (t-distribution) for the mean will be presented for continuous variables, while 95% exact confidence interval will be presented for categorical variables. Values with a decimal point, such as mean, standard deviation, and percentage, will be rounded to two decimal places.

6.3 Handling of Withdrawal and Missing Data
All evaluation data will be analyzed as is without imputation for missing data.

In the analysis of duration of disease, missing month of the date of epilepsy diagnosis will be substituted with June and missing day will be substituted with 15. If the year is missing, the date of epilepsy diagnosis will be handled as missing data. If imputation results in negative duration of disease, the duration of disease will be 0.

6.4 Adjustment for covariate
Adjustment for covariate is not planned.

6.5 Multiple Comparison or Multiplicity of Testing
Multiple comparison or analysis of multiplicity of testing is not planned.

6.6 Interim Analysis
Interim analysis is not planned.

6.7 Sensitivity Analysis
Sensitivity analysis is not planned.
6.8 Study Participation

6.8.1 Subject Disposition
Subjects who completed the study and subjects who discontinued the study are presented using frequency and percentage. For those who discontinued the study, reason for discontinuation is presented using frequency and percentage.

6.8.2 Subject Disposition by Study Site
Subjects who completed the study and subjects who discontinued the study are presented by study site using frequency and percentage.

6.8.3 Protocol Deviation
For subjects with protocol deviation, excluding those who discontinued the study, reason for deviation is presented using frequency and percentage.

6.8.4 Analysis Sets
Number of subjects included in the Safety Analysis Set, FAS, and PPS is presented. Reason for exclusion from the data set is presented using frequency and percentage.

6.9 Demographic Information
Demographic and baseline disease characteristics, past/current disease, previous/concomitant medication, previous/concomitant medication (anti-epileptic drug), and concomitant non-pharmacological therapy at the time of enrollment are analyzed in the FAS.

- **Demographic characteristics**
Continuous data (age, height, body weight, BMI) is presented using descriptive statistics (number of subjects, mean, standard deviation, median (minimum, maximum)), and categorical data (age group (<65 years or ≥65 years), sex) is presented using frequency and percentage.
  - BMI (kg/m²) = body weight (kg) / height (m)²

- **Baseline disease characteristics (epilepsy diagnosis: duration of disease, ILAE classification, cause, seizure type and frequency: partial-onset seizure with or without secondary generalization, simple partial seizure with motor involvement, complex partial seizure, complex partial seizure with secondary generalization, other seizures)**
Continuous data (duration of disease, partial-onset seizure with or without secondary generalization, simple partial seizure with motor involvement, complex partial seizure, complex partial seizure with secondary generalization, other seizures) is presented using descriptive statistics (number of subjects, mean, standard deviation, median (minimum, maximum)); for seizure type and frequency, 1\textsuperscript{st} and 3\textsuperscript{rd} quartiles are presented as well. Categorical data (ILAE classification, cause) is presented using frequency and percentage.

- Duration of disease (years) = (date of signing the consent form – date of initial diagnosis) / 365.25
- Seizure frequency = (number of seizures / (date of Visit 1 – date of 8 weeks prior to Visit 1)) x 28

- Past and Current Medical History
Diseases/procedures in past/current medical history are coded using SOC (System Organ Class) and PT (Preferred Term) of MedDRA (21.0 version). Represented codes are presented using frequency, percentage, and count.

Past medical history is defined as medical history ‘not ongoing’ at the time of visit, while current medical history is defined as medical history ‘ongoing’ at the time of visit.

- Previous and Concomitant Medication
Previous and concomitant medications are coded using 1\textsuperscript{st} level (Anatomical main group) and 4\textsuperscript{th} level (Chemical subgroup) of ATC classification system (2018 version). Represented codes are presented using frequency, percentage, and count.

Previous medications are defined as those taken before the study treatment, while concomitant medications are defined as those taken after the study treatment. Any medication for which the date of last dose is ‘UK’ (thus, it is not known whether the drug was administered before or after the study treatment) is included in both previous and concomitant medications.

- Previous and Concomitant Medications (anti-epileptic drugs)
Previous and concomitant medications (anti-epileptic drugs) are coded using 4\textsuperscript{th} level (Chemical subgroup) and 5\textsuperscript{th} level (Chemical substance) of ATC classification system (2018 version).
Represented codes are presented using frequency, percentage, and count.

Previous medications are defined as those taken before the study treatment, while concomitant medications are defined as those taken after the study treatment. Any medication for which the date of last dose is ‘UK’ (thus, it is not known whether the drug was administered before or after the study treatment) is included in both previous and concomitant medications.

- **Concomitant Non-Pharmacological Therapy**

Concomitant non-pharmacological therapies are coded using SOC (System Organ Class) and PT (Preferred Term) of MedDRA (21.0 version). Represented codes are presented using frequency, percentage, and count.

6.10 **Treatment Compliance**

Treatment compliance during the study period is calculated as follows, and presented using descriptive statistics (number of subjects, mean, standard deviation, median, minimum, and maximum).

\[
\text{Actual number of administration days during the study period} \times 100
\]

\[
\text{Expected number of administration days during the study period}
\]

6.11 **Efficacy Analysis**

In the efficacy analyses, seizure frequency is calculated as follows.

- Seizure frequency during the screening period = \( \frac{\text{number of seizure}}{\text{(date of Visit 1 – date of 8 weeks prior to Visit 1)}} \times 28 \)
- Seizure frequency during the titration period = \( \frac{\text{number of seizure}}{\text{(date of end of Visit 3 or date of withdrawal during the titration period – date of start of Visit 2)}} \times 28 \)
- Seizure frequency during the maintenance period = \( \frac{\text{number of seizure}}{\text{(date of end of Visit 5 or date of withdrawal during the maintenance period – date of start of Visit 4)}} \times 28 \)
6.11.1 Analysis of primary efficacy endpoint
50% responder rate for partial onset seizure with or without secondary generalization
Seizure frequency during the screening period and seizure frequency during the maintenance
period in 50% responders, defined as subjects achieving at least 50% reduction in the frequency
of partial onset seizures with or without secondary generalization during the maintenance period
compared to baseline, are presented using descriptive statistics (number of subjects, mean,
standard deviation, median (minimum, maximum), 1\textsuperscript{st} quartile, and 3\textsuperscript{rd} quartile), rate, and 95%
CI. Seizure frequency is calculated as follows.

6.11.2 Analysis of secondary efficacy endpoints
1) 75% responder rate for partial onset seizure with or without secondary generalization
Seizure frequency during the screening period and seizure frequency during the maintenance
period in 75% responders, defined as subjects achieving at least 75% reduction in the frequency
of partial onset seizures with or without secondary generalization during the maintenance period
compared to baseline, are presented using descriptive statistics (number of subjects, mean,
standard deviation, median (minimum, maximum), 1\textsuperscript{st} quartile, and 3\textsuperscript{rd} quartile), rate, and 95%
CI. Seizure frequency is calculated as follows.

2) 100% responder (seizure-free) rate for partial onset seizure with or without secondary
generalization
Seizure frequency during the screening period and seizure frequency during the maintenance
period in 100% responders (seizure-free subjects), defined as subjects achieving 100% reduction
in the frequency of partial onset seizures with or without secondary generalization during the
maintenance period compared to baseline, are presented using descriptive statistics (number of
subjects, mean, standard deviation, median (minimum, maximum), 1\textsuperscript{st} quartile, and 3\textsuperscript{rd} quartile), rate, and 95%
CI. Seizure frequency is calculated as follows.

3) Percent change from baseline in the frequency of partial onset seizure with or without
secondary generalization during the titration period and maintenance period
Frequency of partial onset seizure with or without secondary generalization during the screening
period, titration period, and maintenance period is presented using descriptive statistics (number
of subjects, mean, standard deviation, median (minimum, maximum), 1\textsuperscript{st} quartile, and 3\textsuperscript{rd} quartile).
Also, percent change in the frequency of partial onset seizure with or without secondary
generalization during the titration period and maintenance period compared to the screening
period is calculated and presented using descriptive statistics (number of subjects, mean, standard deviation, median (minimum, maximum), 1st quartile, and 3rd quartile) along with corresponding 95% CI. Seizure frequency is calculated as follows.

4) 50% responder rate for secondary generalized tonic-clonic seizure
Seizure frequency during the screening period and seizure frequency during the maintenance period in 50% responders, defined as subjects achieving at least 50% reduction in the frequency of secondary generalized tonic-clonic seizure during the maintenance period compared to baseline, are presented using descriptive statistics (number of subjects, mean, standard deviation, median (minimum, maximum), 1st quartile, and 3rd quartile), rate, and 95% CI. Seizure frequency is calculated as follows.

5) 75% responder rate for secondary generalized tonic-clonic seizure
Seizure frequency during the screening period and seizure frequency during the maintenance period in 75% responders, defined as subjects achieving at least 75% reduction in the frequency of secondary generalized tonic-clonic seizure during the maintenance period compared to baseline, are presented using descriptive statistics (number of subjects, mean, standard deviation, median (minimum, maximum), 1st quartile, and 3rd quartile), rate, and 95% CI. Seizure frequency is calculated as follows.

6) 100% responder (seizure free) rate for secondary generalized tonic-clonic seizure
Seizure frequency during the screening period and seizure frequency during the maintenance period in 100% responders (seizure-free subjects), defined as subjects achieving 100% reduction in the frequency of secondary generalized tonic-clonic seizure during the maintenance period compared to baseline, are presented using descriptive statistics (number of subjects, mean, standard deviation, median (minimum, maximum), 1st quartile, and 3rd quartile), rate, and 95% CI. Seizure frequency is calculated as follows.

7) Percent change from baseline in the frequency of secondary generalized tonic-clonic seizure during the titration period and maintenance period
Frequency of secondary generalized tonic-clonic seizure during the screening period, titration period, and maintenance period is presented using descriptive statistics (number of subjects, mean, standard deviation, median (minimum, maximum), 1st quartile, and 3rd quartile). Also, percent change in the frequency of secondary generalized tonic-clonic seizure during the
titration period and maintenance period compared to the screening period is calculated and presented using descriptive statistics (number of subjects, mean, standard deviation, median (minimum, maximum), 1\textsuperscript{st} quartile, and 3\textsuperscript{rd} quartile) along with corresponding 95% CI. Seizure frequency is calculated as follows.

6.12 Safety Analysis

6.12.1 Extent of Exposure

With regard to extent of exposure during the study period, duration of treatment and total dose in the titration period and maintenance period are calculated as follows and presented using descriptive statistics (number of subjects, mean, standard deviation, median, minimum, and maximum).

\[
\text{Duration of treatment in the titration period (days)} = \text{date of last dose} - \text{date of first dose} + 1
\]

\[
\text{Duration of treatment in the maintenance period (days)} = \text{date of last dose} - \text{date of first dose} + 1
\]

\[
\text{Total dose (mg)} = \text{sum of doses administered (daily dose x number of dosing days)}
\]

6.12.2 Adverse Events

Treatment-emergent adverse events (TEAEs) were analyzed (TEAEs refer to adverse events that were absent before study treatment and emerged after study treatment, or adverse events that were present before study treatment and worsened after study treatment). Subjects who experienced more than one TEAE are counted once.

ADRs are related adverse events considered as probably related or possibly related by the investigator, for which causal relationship to the investigational product cannot be ruled out. Those considered as not related by the investigator are defined as unrelated adverse events.

Incidence of TEAEs, ADRs, SAEs, and AEs leading to treatment discontinuation is presented using frequency and percentage along with 95% CI.

AEs, ADRs, SAEs, and AEs leading to treatment discontinuation are coded using SOC (System Organ Class) and PT (Preferred Term) of MedDRA and analyzed by causality and severity. Represented codes are presented using the number of subjects and incidence. Listing will be
provided for SAEs.

6.12.3 Laboratory Tests
For laboratory tests that are continuous variables, results at baseline, Week 36 (Visit 5), end-of-study visit, and follow-up as well as the change from baseline to the last dose of study treatment are presented using descriptive statistics (number of subjects, mean, standard deviation, median, minimum, and maximum). Categorical variables are classified as ‘Normal’ or ‘Abnormal’ and the change from baseline to the last dose of study treatment is summarized using a shift table to present the frequency and percentage. Percentage is based on subjects who have results both at baseline and at subsequent timepoints.
In addition, laboratory test results will be classified into low (L), normal (N), or high (H) (LNH). To compare the laboratory parameters during the treatment period, 3 x 3 shift table presenting the LNH classification at baseline and LNH classification at each visit will be presented.

6.12.4 Vital Signs
Results at baseline (Visit 1), Week 6 (Visit 2), Week 12 (Visit 3), Week 24 (Visit 4), Week 36 (Visit 5), end-of-study visit, and follow-up as well as the change from baseline to each timepoint post-treatment are presented using descriptive statistics (number of subjects, mean, standard deviation, median, minimum, and maximum).

6.12.5 Physical Measurement (Body Weight)
Results at baseline (Visit 1), Week 36 (Visit 5), end-of-study visit, and follow-up as well as the change from baseline to each timepoint post-treatment are presented using descriptive statistics (number of subjects, mean, standard deviation, median, minimum, and maximum).

7. Plan for Revision of Analysis Method
Revision of analysis method is not planned.

8. TLF shell
List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Table Description</th>
</tr>
</thead>
</table>

CONFIDENTIAL
SD 0400 A v2.0
Statistical Analysis Plan
19/22 page
Effective Date: 03-May-2018
<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>s1</td>
<td>14.1.1 Subject Disposition - All Enrolled Subject</td>
</tr>
<tr>
<td>s2</td>
<td>14.1.2 Subject Disposition by Study Site - All Enrolled Subject</td>
</tr>
<tr>
<td>s3</td>
<td>14.1.3 Major Protocol Deviations - All Enrolled Subject</td>
</tr>
<tr>
<td>s4</td>
<td>14.1.4 Analysis Sets - All Enrolled Subject</td>
</tr>
<tr>
<td>b1</td>
<td>14.1.5 Demographic Characteristics - Full Analysis Set</td>
</tr>
<tr>
<td>b2</td>
<td>14.1.6 Baseline Disease Characteristics - Full Analysis Set</td>
</tr>
<tr>
<td>b3</td>
<td>14.1.7 Past Medical History - Full Analysis Set</td>
</tr>
<tr>
<td>b4</td>
<td>14.1.8 Current Medical History - Full Analysis Set</td>
</tr>
<tr>
<td>b5</td>
<td>14.1.9 Previous Medications - Full Analysis Set</td>
</tr>
<tr>
<td>b6</td>
<td>14.1.10 Concomitant Medications - Full Analysis Set</td>
</tr>
<tr>
<td>b7</td>
<td>14.1.11 Previous Medications (anti-epileptic drugs) - Full Analysis Set</td>
</tr>
<tr>
<td>b8</td>
<td>14.1.12 Concomitant Medications (anti-epileptic drugs) - Full Analysis Set</td>
</tr>
<tr>
<td>b9</td>
<td>14.1.13 Concomitant Non-Pharmacological Therapy - Full Analysis Set</td>
</tr>
<tr>
<td>e1_1</td>
<td>14.2.2.1 50% Responder Rate for Partial Onset Seizures with or without Secondary Generalization - Full Analysis Set</td>
</tr>
<tr>
<td>e1_2</td>
<td>14.2.2.2 50% Responder Rate for Partial Onset Seizures with or without Secondary Generalization - Per Protocol Set</td>
</tr>
<tr>
<td>e2_1</td>
<td>14.2.3.1 75% Responder and 100% Responder (Seizure-Free) Rate for Partial Onset Seizures with or without Secondary Generalization - Full Analysis Set</td>
</tr>
<tr>
<td>e2_2</td>
<td>14.2.3.2 75% Responder and 100% Responder (Seizure-Free) Rate for Partial Onset Seizures with or without Secondary Generalization - Per Protocol Set</td>
</tr>
<tr>
<td>e3_1</td>
<td>14.2.4.1 Percent Change in the Frequency of Partial Onset Seizures with or without Secondary Generalization during the Titration Period and Maintenance Period compared to Screening Period - Full Analysis Set</td>
</tr>
<tr>
<td>e3_2</td>
<td>14.2.4.2 Percent Change in the Frequency of Partial Onset Seizures with or without Secondary Generalization during the Titration Period and Maintenance Period compared to Screening Period - Per Protocol Set</td>
</tr>
<tr>
<td>e4_1</td>
<td>14.2.5.1 - 50% Responder, 75% Responder, and 100% Responder (Seizure-Free) Rate for Secondary Generalized Tonic-Clonic Seizure - Full Analysis Set</td>
</tr>
<tr>
<td>e4_2</td>
<td>14.2.5.2 - 50% Responder, 75% Responder, and 100% Responder (Seizure-Free) Rate for Secondary Generalized Tonic-Clonic Seizure - Per Protocol Set</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>e5_1</td>
<td>14.2.6.1 Percent Change in the Frequency of Secondary Generalized Tonic-Clonic Seizure during the Titration Period and Maintenance Period compared to Screening Period - Full Analysis Set</td>
</tr>
<tr>
<td>e5_2</td>
<td>14.2.6.2 Percent Change in the Frequency of Secondary Generalized Tonic-Clonic Seizure during the Titration Period and Maintenance Period compared to Screening Period - Per Protocol Set</td>
</tr>
<tr>
<td>ex1</td>
<td>14.3.1 Extent of Exposure - Safety Analysis Set</td>
</tr>
<tr>
<td>a1</td>
<td>14.3.2 Summary of Adverse Events - Safety Analysis Set</td>
</tr>
<tr>
<td>a2</td>
<td>14.3.3 Incidence of Treatment-Emergent Adverse Events by System Organ Class - Safety Analysis Set</td>
</tr>
<tr>
<td>a3</td>
<td>14.3.4 Incidence of Treatment-Emergent Adverse Drug Reactions by System Organ Class - Safety Analysis Set</td>
</tr>
<tr>
<td>a4</td>
<td>14.3.5 Incidence of Treatment-Emergent Serious Adverse Events by System Organ Class - Safety Analysis Set</td>
</tr>
<tr>
<td>a5</td>
<td>14.3.6 Incidence of Adverse Events Leading to Treatment Discontinuation by System Organ Class - Safety Analysis Set</td>
</tr>
<tr>
<td>a6</td>
<td>14.3.7 List of Treatment-Emergent Serious Adverse Events - Safety Analysis Set</td>
</tr>
<tr>
<td>a7</td>
<td>14.3.8 Incidence of Treatment-Emergent Adverse Events by System Organ Class and Severity - Safety Analysis Set</td>
</tr>
<tr>
<td>a8</td>
<td>14.3.9 Incidence of Treatment-Emergent Adverse Events by System Organ Class and Causality - Safety Analysis Set</td>
</tr>
<tr>
<td>l1</td>
<td>14.4.1.1 Hematology - Safety Analysis Set</td>
</tr>
<tr>
<td>l2</td>
<td>14.4.1.2 Blood Chemistry - Safety Analysis Set</td>
</tr>
<tr>
<td>l3</td>
<td>14.4.1.3 Urinalysis - Safety Analysis Set</td>
</tr>
<tr>
<td>l4</td>
<td>14.4.2 Urinalysis: Normal/Abnormal - Safety Analysis Set</td>
</tr>
<tr>
<td>l5</td>
<td>14.4.3.1 Hematology: LNH - Safety Analysis Set</td>
</tr>
<tr>
<td>l6</td>
<td>14.4.3.2 Blood Chemistry: LNH - Safety Analysis Set</td>
</tr>
<tr>
<td>l7</td>
<td>14.4.3.3 Urinalysis: LNH - Safety Analysis Set</td>
</tr>
<tr>
<td>v1</td>
<td>14.4.4 Vital Signs - Safety Analysis Set</td>
</tr>
<tr>
<td>pe1</td>
<td>14.4.5 Physical Measurement (Body Weight) - Safety Analysis Set</td>
</tr>
</tbody>
</table>
9. Roles and Responsibilities

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biostatistician</td>
<td>PPD</td>
<td>Statistical analysis</td>
</tr>
<tr>
<td>QC Biostatistician</td>
<td>PPD</td>
<td>Quality control for the statistical analysis process</td>
</tr>
</tbody>
</table>

10. Applied SOPs

<table>
<thead>
<tr>
<th>SOP No.</th>
<th>SOP Version</th>
<th>SOP Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>0400</td>
<td>2.0_23-Oct-2017</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>0401</td>
<td>3.0_01-Jun-2017</td>
<td>Statistical Analysis Process</td>
</tr>
</tbody>
</table>

11. Applied SOP SDs

<table>
<thead>
<tr>
<th>SD No.</th>
<th>SD Version</th>
<th>SD Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>SD 0400 A</td>
<td>2.0_03-May-2018</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>SD 0408 A</td>
<td>3.0_23-Oct-2017</td>
<td>STAT Master File Index</td>
</tr>
</tbody>
</table>